During today’s pre-market session, shares of Bone Biologics Corporation (NASDAQ: BBLG) were showing a notable upward trend, rising 82.21% to $7.58 as of the last check. Significant business activities, including a significant patent application and an update on Nasdaq compliance, preceded the notable increase in BBLG’s stock value.
A Patent Application Promotes Bone Treatment Innovation
Bone Biologics (BBLG) has submitted a new patent application to the USPTO for its innovative NELL-1 protein technology. The application focuses on the potential therapeutic applications of recombinant human NELL-1 (rhNELL-1) polypeptide compositions to treat a variety of bone-related conditions.
This scientific discovery represents a major turning point in Bone Biologics’ ongoing attempts to develop more potent treatments, particularly for patients having spinal fusion procedures. If granted, the patent will bolster BBLG’s intellectual property assets and long-term clinical development trajectory.
Nasdaq Compliance Has Been Restored
In a different statement, Bone Biologics stated that it is now in compliance with Listing Rule 5550(a)(2), which requires a minimum bid price, as required by the Nasdaq. The Nasdaq Stock Market LLC previously notified the business that its common stock now satisfies all requirements for continuing listing on the Nasdaq Capital Market.
On April 7, 2025, Nasdaq first informed Bone Biologics that the firm was noncompliant after its shares had fallen below $1.00 per share for 30 straight working days. In order to fix this, BBLG has to keep the closing bid price at least $1.00 for ten consecutive trading sessions, a milestone Bone Biologics officially attained on June 24, 2025.
Strategic Momentum and Investor Confidence
Complete listing compliance and a possible patent filing are two events that show Bone Biologics’ strategic goals have advanced significantly. BBLG is positioned well within the biomedical innovation environment thanks to the notable stock rise, which reflects rising investor confidence in the company’s pipeline and operational prospects.
